Vaccines

A pharmaceutical composition comprising

• (a) a compound of Formula I
• wherein
• is a single or double bond;
• W is —CHO;
• V is hydrogen or ORx;
• Y is CH2, —O—, —NR—, or —NH—;
• Z is hydrogen;
• a cyclic or acyclic, optionally substituted moiety selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, arylalkyl, heteroacyl, and heteroaryl;
• or a carbohydrate domain having the structure:
• wherein each occurrence of R1 is Rx or a carbohydrate domain having the structure:
• wherein:
• each occurrence of a, b, and c is independently 0, 1, or 2;
• d is an integer from 1-5, wherein each d bracketed structure may be the same or different;
• with the proviso that the d bracketed structure represents a furanose or a pyranose moiety, and the sum of b and c is 1 or 2;
• R0 is hydrogen;
• an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates;
• or an optionally substituted moiety selected from the group consisting of acyl, C1-10 aliphatic, C1-6 heteroaliphatic, 6-10-membered aryl, arylalkyl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
• each occurrence of Ra, Rb, Rc, and Rd is independently hydrogen, halogen, OH, OR, ORx, NR2, NHCOR, or an optionally substituted group selected from acyl, C1-10 aliphatic, C1-6 heteroaliphatic, 6-10-membered aryl, arylalkyl, 5-10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, sulfur;
• 4-7-membered heterocyclyl having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
• R2 is hydrogen, halogen, OH, OR, OC(O)R4, OC(O)OR4, OC(O)NHR4, OC(O)NRR4, OC(O)SR4, NHC(O)R4, NRC(O)R4, NHC(O)OR4, NHC(O)NHR4, NHC(O)NRR4, NHR4, N(R4)2, NHR4, NRR4, N3, or an optionally substituted group selected from C1-10 aliphatic, C1-6 heteroaliphatic, 6-10-membered aryl, arylalkyl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 4-7-membered heterocyclyl having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
• R3 is hydrogen, halogen, CH2OR1, or an optionally substituted group selected from the group consisting of acyl, C1-10 aliphatic, C1-6 heteroaliphatic, 6-10-membered aryl, arylalkyl, 5-10-membered heteroaryl having 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, 4-7-membered heterocyclyl having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur,
• R4 is -T-Rz, —C(O)-T-Rz, —NH-T-Rz, —O-T-Rz, —S-T-Rz, —C(O)NH-T-Rz, C(O)O-T-Rz, C(O)S-T-Rz, C(O)NH-T-O-T-Rz, —O-T-Rz, -T-O-T-Rz, -T-S-T-Rz, or
• wherein
• X is —O—, —NR—, or T-Rz;
• T is a covalent bond or a bivalent C1-26 saturated or unsaturated, straight or branched, aliphatic or heteroaliphatic chain;
• and
• Rz is hydrogen, halogen, —OR, —ORx, —OR1, —SR, NR2, —C(O)OR, —C(O)R, —NHC(O)R, —NHC(O)OR, NC(O)OR, or an optionally substituted group selected from acyl, arylalkyl, heteroarylalkyl, C1-6 aliphatic, 6-10-membered aryl, 5-10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 4-7-membered heterocyclyl having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
• each occurrence of Rx is independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates;
• each occurrence of R is independently hydrogen, an optionally substituted group selected from acyl, arylalkyl, 6-10-membered aryl, C1-6 aliphatic, or C1-6 heteroaliphatic having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, or:
• two R on the same nitrogen atom are taken with the nitrogen atom to form a 4-7-membered heterocyclic ring having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
• and
• (b) a TLR4 agonist selected from the group consisting of Lipid A, MPL, 3D-MPL, GLA, LPS, RC-529, E6020, ONO-4007, CRX-527, CRX-547, GSK1795091, CRX-601, SLA, PET-lipid A, PHAD, 3D-PHAD, 3D-(6-acyl)-PHAD, OM-294, OM-174, OK-432, 2B182C, and EcML.